XLO — Xilio Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1840233 ·
Last close
$7.54
Market Cap
$53.26M
52W High
$11.30
52W Low
$6.47
ADV30
13,768
Next earnings
—
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 18,692,000 — -3,491,000 -6,373,000 154,254,000 136,040,000 81,990,000
Mar 2026 12,648,000 — -14,112,000 -9,529,000 163,487,000 150,333,000 90,943,000
Dec 2025 13,686,000 — -11,836,000 10,360,000 154,685,000 137,531,000 119,412,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-56,897,000
Investing CF
$-728,000
Financing CF
$76,067,000
CapEx
$-728,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-440,639,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-41,188,000
Pretax Income TTM
$-11,490,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$55,010,000
EBITDA
$-39,869,000
Free Cash Flow
$-36,345,752
Enterprise Value
$-59,180,344
Total Cash
$122,182,000
Total Debt
$5,960,000
Shares Out
7,063,982
Trailing EPS
$0.65
Book Value
$10.36
ROE
-38.2%
ROA
-19.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 43,766,000 -41,982,000 -35,036,000 154,685,000 119,412,000 35,273,000 -4,992,000
Dec 2024 6,344,000 -59,645,000 -58,241,000 71,075,000 53,477,000 17,598,000 -18,378,000
Dec 2023 0 -79,133,000 -76,404,000 60,926,000 24,099,000 36,827,000 -68,620,000
Dec 2022 0 -89,149,000 -88,222,000 139,165,000 33,518,000 105,647,000 -75,723,000

TTM Snapshot

Revenues TTM
$64,092,000
NetIncome TTM
$-21,829,000
OpCashFlow TTM
—
Assets (Latest)
$154,254,000
Forward EPS
$-0.58

Peers — same industry

TickerNameMarket CapLastDaily %
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —
HRTX HERON THERAPEUTICS, INC. /DE/ $53.70M $0.28 —
IBIO iBio, Inc. $52.71M $0.75 —
VRCA Verrica Pharmaceuticals Inc. $53.94M $3.14 —
GANX Gain Therapeutics, Inc. $52.54M $1.18 —

News headlines (Yahoo Finance, 1h cache)

Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-11-10 12:30 · Yahoo
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
2026-11-03 21:30 · Yahoo
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
2026-10-26 11:30 · Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:30 · Yahoo
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-08-12 11:30 · Yahoo
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
2026-06-29 11:30 · Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 20:30 · Yahoo
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
2026-04-16 11:30 · Yahoo
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 12:40 · Yahoo
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
2026-04-17 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.